Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
2kDbanvE7ng8nrDq
Listen
